logo

EVH

Evolent Health·NYSE
--
--(--)
--
--(--)
0.78 / 10
Underperform

EVH's fundamental health is subdued, scoring only 0.8/10. Key concerns include a negative ROE of -16.30% and an annualized return on equity of -21.74%, alongside a -26.24% YoY revenue decline. Although the quick ratio (2.20) and interest coverage ratio (15.51) offer some liquidity and solvency support, they are insufficient to offset profitability and growth challenges. Historical back-tests for most factors show negative one-month returns, reinforcing the weak fundamental stance.

Fundamental(0.78)SentimentTechnical

Analysis Checks(5/10)

Annualized return on equity (%)
Value-21.74
Score3/3
Weight-13.00%
1M Return2.71%
Accounts receivable turnover ratio
Value3.51
Score1/3
Weight17.98%
1M Return-4.64%
Quick ratio
Value2.20
Score2/3
Weight7.24%
1M Return-1.58%
Shareholders’ equity attributable to parent company (growth rate compared to beginning of year %)
Value-15.88
Score0/3
Weight31.63%
1M Return-9.17%
Total profit / EBIT (%)
Value151.16
Score0/3
Weight31.82%
1M Return-10.51%
Long-term debt to working capital ratio (%)
Value8.43
Score2/3
Weight2.55%
1M Return-0.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight10.79%
1M Return-2.49%
Operating revenue (YoY growth rate %)
Value-26.24
Score1/3
Weight15.23%
1M Return-4.28%
ROE (%)
Value-16.30
Score3/3
Weight-13.00%
1M Return2.71%
Cash-MV
Value-0.72
Score1/3
Weight8.76%
1M Return-2.12%
Is EVH undervalued or overvalued?
  • EVH scores 0.78/10 on fundamentals and holds a Premium valuation at present. Backed by its -14.78% ROE, -6.24% net margin, -1.72 P/E ratio, 0.38 P/B ratio, and -70.65% earnings growth, these metrics solidify its Underperform investment rating.